Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Marinde J. G. Bond(Utrecht University), Johannes J.M. Kwakman(Utrecht University), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers), Stefan Ibach, Cornelis J.A. Punt(Utrecht University), Sara Lonardi(Istituto Oncologico Veneto), Sabina Murgioni(Istituto Oncologico Veneto), Miriam Koopman(Utrecht University), Maarten van Smeden(Utrecht University), Anne M. May(Utrecht University), Daniele Rossini(Azienda Ospedaliera Universitaria Pisana), Carlotta Antoniotti(University of Pisa), Chiara Cremolini(University of Pisa), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Koen Degeling(Cancer Council Victoria)
Cited by 6
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k